UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $655,000 Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 50.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,249 shares of the company’s stock after selling 8,309 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Dr. Reddy’s Laboratories were worth $655,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Dr. Reddy’s Laboratories by 318.0% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company’s stock valued at $28,411,000 after purchasing an additional 283,700 shares in the last quarter. Fisher Asset Management LLC raised its position in Dr. Reddy’s Laboratories by 59.4% in the 3rd quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock valued at $39,034,000 after buying an additional 183,146 shares during the last quarter. Millennium Management LLC lifted its stake in Dr. Reddy’s Laboratories by 61.4% during the 2nd quarter. Millennium Management LLC now owns 332,502 shares of the company’s stock valued at $25,333,000 after acquiring an additional 126,472 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Dr. Reddy’s Laboratories by 12.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock valued at $76,455,000 after acquiring an additional 114,294 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Dr. Reddy’s Laboratories by 219.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 155,481 shares of the company’s stock worth $12,353,000 after acquiring an additional 106,796 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors.

Dr. Reddy’s Laboratories Trading Up 1.7 %

Shares of Dr. Reddy’s Laboratories stock opened at $15.37 on Friday. The firm has a market cap of $12.83 billion, a PE ratio of 24.55 and a beta of 0.53. Dr. Reddy’s Laboratories Limited has a 1 year low of $13.31 and a 1 year high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.36. The stock has a fifty day moving average price of $14.80 and a 200-day moving average price of $15.38.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Barclays reduced their price objective on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Finally, Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.